| Symbol | ESLA |
|---|---|
| Name | ESTRELLA IMMUNOPHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 5858 HORTON STREET,SUITE 370, EMERYVILLE, California, 94608, United States |
| Telephone | +1 510 - 318-9098 |
| Fax | — |
| — | |
| Website | https://www.estrellabio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001844417 |
| Description | Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eurekas ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eurekas ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE). Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Estrella Immunopharma, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003573 <b>Size:</b> 10 KB
Read moreEstrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Read moreEstrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Read moreEstrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Read moreEstrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read more